Nabsys Reveals Groundbreaking Research on Disease Insights with OhmX™ Platform at ASHG 2025

Nabsys Showcases Innovations in Disease Insights at ASHG 2025

Nabsys 2.0, LLC, an innovative leader in electronic genome mapping technology, made a significant impact at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) held in Boston, MA. Their presentations emphasized groundbreaking insights acquired through their OhmX™ Platform, showcasing its application across various medical conditions, including interstitial cystitis/bladder pain syndrome (IC/BPS).

Multi-Omics Study Reveals Psychiatric Comorbidities

In a poster presented by esteemed researchers from Boston Children’s Hospital, a comprehensive multi-omics study was unveiled. This study investigated correlation patterns between IC/BPS and psychiatric conditions. Key findings indicated that a staggering 70% of individuals diagnosed with IC/BPS were also identified as having psychiatric disorders, mainly anxiety and depression.

The rigorous analysis involved 248 patients from the Boston Children’s cohort, which was meticulously compared against a control group from the Maryland Genetics of Interstitial Cystitis Study (MaGIC). Notably, the research identified 13 proteins that show differential expression and suggested that while no single gene directly links to IC/BPS risk, new potential candidates emerged, adding depth to the genetic understanding of the syndrome.

Importance of Accurate Structural Variant Detection

Nabsys's OhmX Platform, integrating electronic genome mapping (EGM), demonstrated its capability to efficaciously identify structural variants linked to hematological malignancies. The platform’s application in a clinical setting enables streamlined analysis providing cost-effective and accurate results, enhancing the diagnostics landscape in genomic testing.

One notable application discussed was the use of EGM for mapping significant genetic abnormalities such as TP53 deletions and reciprocal gene fusions. The precision of EGM in linking genetic variants to clinical outcomes furthers its value in cancer research.

Additionally, the platform’s advanced capabilities were exhibited in the analysis of repeat expansion disorders like Fragile X syndrome, showcasing an innovative new pipeline termed RepX Analysis for Repeat Disorders, pushing boundaries in genomic testing accuracy and speed.

CRISPR/Cas9 Enhancements for Improved Detection

Further enhancing its technological suite, Nabsys demonstrated the application of CRISPR/Cas9 technology, which serves an instrumental role in repairing double-strand DNA breaks during EGM sample preparation. This advancement aids in the preservation of sample integrity, enabling more reliable detection of structural variants.

Dr. Barrett Bready, founder and CEO of Nabsys, expressed his enthusiasm for the research presented. He highlighted, "Our proprietary methodologies have provided remarkable accuracy in identifying hematological cancer markers, representing our commitment to innovating and refining genomic analyses. The integration of CRISPR/Cas9 in our workflow exemplifies our dedication to overcoming challenges in structural variant detection.”

Conclusion: Next Steps in Genomic Understanding

The presentations at ASHG 2025 not only displayed Nabsys's groundbreaking research findings but also emphasized the urgent need for improved understanding of complex diseases like IC/BPS, particularly their impact on mental health. As they move forward, Nabsys aims to deliver even more consequential insights to clinicians and patients, ultimately enhancing holistic treatment approaches.

To access all presentations from the ASHG Meeting, visit Nabsys's resource section at their official website. As they continue to lead with innovative genomic technologies, the healthcare community eagerly anticipates how their advancements can reshape understanding in genetic research and treatment methodologies.